1. Home
  2. MDGL vs SRAD Comparison

MDGL vs SRAD Comparison

Compare MDGL & SRAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDGL
  • SRAD
  • Stock Information
  • Founded
  • MDGL 2011
  • SRAD 2001
  • Country
  • MDGL United States
  • SRAD Switzerland
  • Employees
  • MDGL N/A
  • SRAD N/A
  • Industry
  • MDGL Biotechnology: Pharmaceutical Preparations
  • SRAD Computer Software: Programming Data Processing
  • Sector
  • MDGL Health Care
  • SRAD Technology
  • Exchange
  • MDGL Nasdaq
  • SRAD Nasdaq
  • Market Cap
  • MDGL 6.1B
  • SRAD 7.7B
  • IPO Year
  • MDGL N/A
  • SRAD 2021
  • Fundamental
  • Price
  • MDGL $298.87
  • SRAD $28.23
  • Analyst Decision
  • MDGL Strong Buy
  • SRAD Strong Buy
  • Analyst Count
  • MDGL 9
  • SRAD 15
  • Target Price
  • MDGL $420.63
  • SRAD $27.40
  • AVG Volume (30 Days)
  • MDGL 302.3K
  • SRAD 2.2M
  • Earning Date
  • MDGL 08-06-2025
  • SRAD 08-12-2025
  • Dividend Yield
  • MDGL N/A
  • SRAD N/A
  • EPS Growth
  • MDGL N/A
  • SRAD 114.88
  • EPS
  • MDGL N/A
  • SRAD 0.20
  • Revenue
  • MDGL $317,383,000.00
  • SRAD $1,245,020,536.00
  • Revenue This Year
  • MDGL $286.17
  • SRAD $17.66
  • Revenue Next Year
  • MDGL $64.17
  • SRAD $15.21
  • P/E Ratio
  • MDGL N/A
  • SRAD $141.62
  • Revenue Growth
  • MDGL N/A
  • SRAD 23.07
  • 52 Week Low
  • MDGL $200.63
  • SRAD $10.06
  • 52 Week High
  • MDGL $377.46
  • SRAD $28.50
  • Technical
  • Relative Strength Index (RSI)
  • MDGL 56.27
  • SRAD 75.47
  • Support Level
  • MDGL $291.45
  • SRAD $27.25
  • Resistance Level
  • MDGL $311.21
  • SRAD $28.50
  • Average True Range (ATR)
  • MDGL 11.25
  • SRAD 0.89
  • MACD
  • MDGL 2.31
  • SRAD 0.22
  • Stochastic Oscillator
  • MDGL 60.86
  • SRAD 93.92

About MDGL Madrigal Pharmaceuticals Inc.

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

About SRAD Sportradar Group AG

Sportradar Group AG is a technology platform enabling next-generation engagement in sports, and a provider of B2B solutions to the sports betting industry. It generates revenue through two primary sources: subscription-based revenue and revenue sharing. Geographically, it operates in North America, Africa, AsiaPac & Middle East, Europe, and LATAM & Caribbean.

Share on Social Networks: